- Home
- ACI vs ITCI Comparison
ACI vs ITCI Comparison
Compare ACI & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACI
- ITCI
- Stock Information
- Founded
- ACI 1860
- ITCI 2002
- Country
- ACI United States
- ITCI United States
- Employees
- ACI N/A
- ITCI N/A
- Industry
- ACI Food Chains
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- ACI Consumer Staples
- ITCI Health Care
- Exchange
- ACI Nasdaq
- ITCI Nasdaq
- Market Cap
- ACI 11.6B
- ITCI 13.5B
- IPO Year
- ACI 2020
- ITCI N/A
- Fundamental
- Price
- ACI $20.55
- ITCI $128.60
- Analyst Decision
- ACI Buy
- ITCI Buy
- Analyst Count
- ACI 12
- ITCI 13
- Target Price
- ACI $23.52
- ITCI $103.92
- AVG Volume (30 Days)
- ACI 4.7M
- ITCI 2.2M
- Earning Date
- ACI 01-08-2025
- ITCI 02-21-2025
- Dividend Yield
- ACI 2.92%
- ITCI N/A
- EPS Growth
- ACI N/A
- ITCI N/A
- EPS
- ACI 1.78
- ITCI N/A
- Revenue
- ACI $79,930,900,000.00
- ITCI $680,852,000.00
- Revenue This Year
- ACI $2.35
- ITCI $48.28
- Revenue Next Year
- ACI $2.44
- ITCI $37.34
- P/E Ratio
- ACI $11.54
- ITCI N/A
- Revenue Growth
- ACI 0.97
- ITCI 46.62
- 52 Week Low
- ACI $17.00
- ITCI $63.30
- 52 Week High
- ACI $21.75
- ITCI $128.77
- Technical
- Relative Strength Index (RSI)
- ACI 52.33
- ITCI 83.90
- Support Level
- ACI $20.24
- ITCI $126.88
- Resistance Level
- ACI $21.67
- ITCI $128.19
- Average True Range (ATR)
- ACI 0.43
- ITCI 0.41
- MACD
- ACI -0.05
- ITCI -1.30
- Stochastic Oscillator
- ACI 47.66
- ITCI 91.01
About ACI Albertsons Companies Inc.
Albertsons is the second largest supermarket operator in the United States with over 2,200 stores across a variety of banners. About 80% of the firm's sales stem from non-perishable and fresh food, of which 25% comes from its portfolio of private brands. The company operates fuel centers and pharmacies at about 20% and 75% of its store locations, respectively. Albertsons went public in 2020 following years of ownership under private equity firm Cerberus Capital Management, which still owns about a fourth of outstanding shares.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.